Cognition Therapeutics, Inc.
CGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $42 | $37 | $30 | $19 |
| G&A Expenses | $12 | $14 | $13 | $10 |
| SG&A Expenses | $12 | $14 | $13 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $54 | $51 | $43 | $29 |
| Operating Income | -$54 | -$51 | -$44 | -$29 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $20 | $25 | $22 | $17 |
| Pre-Tax Income | -$34 | -$26 | -$21 | -$12 |
| Tax Expense | $0 | $0 | -$22 | $0 |
| Net Income | -$34 | -$26 | $1 | -$12 |
| % Margin | – | – | – | – |
| EPS | -0.85 | -0.86 | -0.74 | -0.73 |
| % Growth | 1.2% | -16.2% | -1.4% | – |
| EPS Diluted | -0.85 | -0.86 | -0.74 | -0.73 |
| Weighted Avg Shares Out | 40 | 30 | 29 | 22 |
| Weighted Avg Shares Out Dil | 40 | 30 | 29 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $22 | $17 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$34 | -$26 | -$21 | -$11 |
| % Margin | – | – | – | – |